What is Immunic?
Immunic is dedicated to developing innovative treatments for chronic inflammatory and autoimmune diseases. The company's focus on oral immunology therapies positions it within a critical segment of the biopharmaceutical market, aiming to provide novel solutions for patients with unmet medical needs. The substantial enterprise-level funding suggests a strong belief in Immunic's scientific approach and therapeutic potential.
How much funding has Immunic raised?
Immunic has raised a total of $1.1B across 4 funding rounds:
Share Placement
$60M
Multiple Rounds
$1B
Share Placement (2022): $60M, investors not publicly disclosed
Stock/Share Issuance (2026): $400M led by Vivo Capital, BVF Partners, TCG Crossover, Avidity Partners, and OrbiMed
Stock/Share Issuance (2026): $400M supported by BVF Partners
Private Equity (2026): $200M, investors not publicly disclosed
Key Investors in Immunic
Vivo Capital
Vivo Capital, founded in 1996, is a global healthcare investment firm with a focus on private and public equity, as well as venture capital.
BVF Partners
BVF Partners L.P. is a San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments since 1993.
TCG Crossover
TCG Crossover (TCGX) is a science-driven investment firm focused on advancing disruptive medicines and investing in breakthrough therapies.
What's next for Immunic?
With this significant influx of capital, Immunic is poised for accelerated development and potential commercialization of its lead drug candidates. The company's strategic financing indicates a move towards scaling operations, advancing clinical trials, and potentially expanding its research and development efforts. This investment will likely fuel further progress in its mission to address debilitating autoimmune and inflammatory conditions, marking a pivotal stage in its corporate journey.
See full Immunic company page
